United Health Products (United Health Products) Risk Assessment

View and export this data going back to . Start your Free Trial

What is United Health Products Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of United Health Products is: No Data: Cannot be evaluated.

Competitive Comparison of United Health Products's Risk Assessment

For the Medical Instruments & Supplies subindustry, United Health Products's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

United Health Products's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, United Health Products's Risk Assessment distribution charts can be found below:

* The bar in red indicates where United Health Products's Risk Assessment falls into.

United Health Products (OTCPK:UEEC) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

United Health Products Risk Assessment Related Terms

Thank you for viewing the detailed overview of United Health Products's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

United Health Products (United Health Products) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » United Health Products Inc (OTCPK:UEEC) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

526 Commerce Circle, Suite No. 120, Mesquite, NV, USA, 89027

Website

https://www.uhpcorp.com

United Health Products Inc is a US-based company. It mainly manufactures and markets a patented hemostatic gauze for the healthcare and wound care sectors. The company's product HemoStyp is derived from regenerated oxidized cellulose, which is naturally designed to absorb exudate from superficial wounds and helps control bleeding. It markets its product to dental and medical markets as well as, sports, military and veterinary sectors, and others. The company's trademarks include Boo Boo Strips; The Ultimate Bandage; Hemostrips; CelluSTAT and Nik Fix.

Executives

Brian David Thom	officer: CEO	10624 S EASTERN AVE., STE A209, HENDERSON NV 89052
Kristofer Heaton	officer: Vice-President Finance, CFO	526 COMMERCE CIRCLE, STE 120, MESQUITE NV 89027
Nate Knight	director	C/O MORSE & MORSE, PLLC, 1400 OLD COUNTRY ROAD, SUITE 302, WESTBURY NY 11590
Louis Schiliro	officer: Chief Operating Officer	10624 S. EASTERN AVENUE, STE. A209, HENDERSON NV 89052
Douglas K Beplate	officer: CEO
Robert J. Denser	director	10624 S. EASTERN AVE., STE. A209, HENDERSON NV 89052
John Vito Capotorto	director	1090 KING GEORGES POST ROAD, SUITE 501, EDISON NJ 08837
Sherman Lazrus	director
Rodney Paul Leibowitz	director	420 EAST 54TH STREET, APARTMENT 15B, NEW YORK NY 10022
Michael R. Wiechnik	director	11 PRESWICK DR., MEDFORD NJ 08055
Richard Rifenburgh	director	2637 E. ATLANTIC BLVD., #133, POMPANO BEACH FL 33062
Phillip David Forman	director, officer: President, Chairman and CEO	1090 KING GEORGES POST RD,501, EDISON NJ 08837
Jan E Chason	director, officer: Chief Financial Officer	120 WALL STREET, SUITE 2401, NEW YORK NY 10005
Kelly Thomas Hickel	director, officer: Chief Executive Officer	1630A 30TH STREET, SUITE 300, BOULDER CO 80301
Patrick Donelan	10 percent owner	3570 LAKEVIEW DRIVE, DELRAY BEACH FL 33445